2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. P2X Receptor

P2X Receptor

Receptor

P2XRs

P2X Receptor

Related Products

PDF 0.88 MB

P2X receptors are a family of seven (P2X1R-P2X7R) cation permeable ligand-gated ion channels (LGICs) that open in response to binding by the extracellular ligand, adenosine 5′-triphosphate (ATP). P2X receptors have a high permeability to Ca2+, Na+, and K+ and are expressed widely throughout the nervous, immune, cardiovascular, skeletal, gastrointestinal, respiratory, and endocrine systems.

P2X receptors are widely expressed in excitatory and non-excitatory cells, such as neuron, glia, platelet, epithelia and macrophage, and participate in many important physiological and pathological processes, including synaptic transmission, pain perception, inflammation, cardiovascular modulation, immunomodulation and tumorigenesis.

P2X Receptor Isoform Specific Products:

P2X Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-15568
    A-317491
    		Antagonist 98.77%
    A-317491 is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux.
    A-317491
  • HY-130605
    BAY-1797
    		Antagonist 99.42%
    BAY-1797 is a potent, orally active, and selective P2X4 antagonist, with an IC50 of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects.
    BAY-1797
  • HY-101418
    JNJ-47965567
    		Antagonist 99.79%
    JNJ-47965567 is a centrally permeable, high-affinity, selective P2X7 antagonist, with pKis of 7.9 and 8.7 for human and rat P2X7, respectively. JNJ-47965567 can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.
    JNJ-47965567
  • HY-100483
    A-804598
    		Antagonist 98.55%
    A-804598 is a CNS penetrant, competitive and selective P2X7 receptor antagonist with IC50s of 9 nM, 10 nM and 11 nM for mouse, rat and human P2X7 receptors, respectively.
    A-804598
  • HY-W033577
    Tricarbonyldichlororuthenium(II) dimer
    		Antagonist ≥98.0%
    Tricarbonyldichlororuthenium(II) dimer is a pharmacological donor of CO releasing. CO releases from Tricarbonyldichlororuthenium(II) dimer prevents gastric mucosal oxidative damage induced by ischemia/reperfusion (I/R) improving gastric blood flow (GBF), decreasing DNA oxidation and inflammatory response on systemic level.
    Tricarbonyldichlororuthenium(II) dimer
  • HY-19888
    GSK-1482160
    		Modulator 98.67%
    GSK-1482160 is an orally available negative allosteric modulator of the P2X7 receptor. P2X7 receptors are involved in the production of pro-inflammatory cytokines, such as Il-1β, by central and peripheral immune cells. GSK-1482160 has the potential for the research of inflammation diseases.
    GSK-1482160
  • HY-108676
    NF023 hexasodium
    		Antagonist 99.7%
    NF023 hexasodium is a selective and competitive P2X1 receptor antagonist, with IC50 values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human P2X1, P2X3, P2X2, and P2X4-mediated responses respectively.
    NF023 hexasodium
  • HY-110237
    BX430
    		Antagonist 99.21%
    BX430 is a potent and selective noncompetitive allosteric human P2X4 receptor channels antagonist with an IC50 of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.
    BX430
  • HY-101910
    PSB-12062
    		Antagonist 98.70%
    PSB-12062 is a potent and selective P2X4 antagonist with an IC50 of 1.38 μM for human P2X4.
    PSB-12062
  • HY-123205
    Oxatomide
    		Antagonist 99.56%
    Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin.
    Oxatomide
  • HY-108675
    PPNDS tetrasodium
    		Antagonist
    PPNDS tetrasodium is a selective and competitive meprin β inhibitor (IC50: 80 nM, Ki: 8 nM), and also inhibits ADAM10 (IC50: 1.2 μM). PPNDS tetrasodium is also a P2X1 receptor antagonist. PPNDS is an agonist for the ATP receptor of Paramecium. PPNDS tetrasodium potently inhibits polymerases from viruses. PPNDS tetrasodium can be used in the research of infection and cancers.
    PPNDS tetrasodium
  • HY-16322
    Minodronic acid
    		Antagonist 99.67%
    Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain.
    Minodronic acid
  • HY-14483
    AF-353
    		Antagonist 99.53%
    AF-353 (Ro-4) is a potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist, with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3.
    AF-353
  • HY-B1901
    Eperisone hydrochloride
    		Antagonist 99.95%
    Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is an orally active antispastic agent with a vasodilator effect, used for the research of muscle stiffness and pain. Eperisone Hydrochloride is a potent and selectively P2X7 receptor antagonist, also shows antagonism for human P2X3. Eperisone Hydrochloride works by relaxing both skeletal muscles and vascularsmooth muscles, demonstrating a variety of effects such as reduction ofmyotonia, improvement of circulationand and suppression of the pain reflex.
    Eperisone hydrochloride
  • HY-135976
    P2X3 antagonist 34
    		Antagonist 99.71%
    P2X3 antagonist 34 is a potent, selective and orally active P2X3 homotrimeric receptor antagonist with IC50s of 25 nM, 92 nM and 126 nM for human P2X3, rat P2X3 and guinea pig P2X3 receptors, respectively. P2X3 antagonist 34 is less active against human, rat and guinea pig P2X2/3 heterotrimeric receptors. P2X3 antagonist 34 has strong anti-tussive effect.
    P2X3 antagonist 34
  • HY-N5025
    Bullatine A
    		Inhibitor ≥98.0%
    Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A is a potent P2X7 antagonist, inhibits ATP-induced cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A attenuates pain hypersensitivity, regardless of the pain models employed.
    Bullatine A
  • HY-109067A
    Opiranserin hydrochloride
    		Antagonist 99.62%
    Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain.
    Opiranserin hydrochloride
  • HY-13954
    A 839977
    		Antagonist 98.74%
    A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta.
    A 839977
  • HY-150270A
    NP-1815-PX sodium
    		Antagonist 99.62%
    NP-1815-PX sodium is a potent and selective P2X4R antagonist. NP-1815-PX sodium has anti-inflammatory activity, and can relieve pain in chronic pain models. NP-1815-PX sodium also inhibits guinea pig tracheal/bronchial smooth muscle (TSM and BSM) contractions.
    NP-1815-PX sodium
  • HY-15568A
    A-317491 sodium salt hydrate
    		Antagonist 99.88%
    A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux.
    A-317491 sodium salt hydrate
P2X Receptor Isoform Comparison

P2X1 Receptor

P2X2 Receptor

P2X3 Receptor

P2X4 Receptor

P2X7 Receptor

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

P2X Receptor Inhibitors, Agonists, Antagonists, Activators & Modulators
Product NameP2X1 ReceptorP2X2 ReceptorP2X3 ReceptorP2X4 ReceptorP2X7 ReceptorPurity    
BzATP triethylammonium salt
p2x1 Receptor
 
P2X3 Receptor
P2X4 Receptor
P2X7 Receptor
98.57%
Sodium metatungstate    
P2X7 Receptor
A-740003    
P2X7 Receptor
99.61%
NF449 octasodium
p2x1 Receptor
    ≥99.0%
KN-62    
P2X7 Receptor
99.45%
P2X4 antagonist-3   
P2X4 Receptor, IC50: 1.2 μM
 
Aurintricarboxylic acid
p2x1 Receptor, IC50: 8.6 nM
 
P2X3 Receptor, IC50: 72.9 nM
  
A 438079    
P2X7 Receptor
99.88%
A 438079 hydrochloride    
P2X7 Receptor
99.99%
5-BDBD   
P2X4 Receptor
 99.94%
α,β-Methylene-ATP trisodium
p2x1 Receptor
 
P2X3 Receptor
 
P2X7 Receptor
99.75%
Gefapixant  
P2X3 Receptor
  99.33%
PPADS tetrasodium
p2x1 Receptor
    
AZ10606120 dihydrochloride    
P2X7 Receptor
99.38%
AZD9056 hydrochloride    
P2X7 Receptor
98.18%
JNJ-55308942    
P2X7 Receptor
99.92%
A-317491  
P2X3 Receptor
  98.77%
BAY-1797   
P2X4 Receptor
 99.42%
JNJ-47965567    
P2X7 Receptor
99.79%
A-804598    
P2X7 Receptor
98.55%
GSK-1482160    
P2X7 Receptor
98.67%
NF023 hexasodium
p2x1 Receptor
    99.7%
BX430   
P2X4 Receptor
 99.21%
PSB-12062   
P2X4 Receptor
 98.70%
Oxatomide    
P2X7 Receptor
99.56%
PPNDS tetrasodium
p2x1 Receptor
    
Minodronic acid 
P2X2 Receptor
P2X3 Receptor
  99.67%
AF-353  
P2X3 Receptor
  99.53%
P2X3 antagonist 34  
P2X3 Receptor
  99.71%
Bullatine A    
P2X7 Receptor
≥98.0%
Opiranserin hydrochloride  
P2X3 Receptor
  99.62%
A 839977    
P2X7 Receptor
98.74%
A-317491 sodium salt hydrate  
P2X3 Receptor
  99.88%
JNJ-54175446    
P2X7 Receptor
99.30%
Eliapixant  
P2X3 Receptor
  99.95%
Oxidized ATP trisodium salt    
P2X7 Receptor
≥98.0%
Lu AF27139    
P2X7 Receptor
99.71%
CE-224535    
P2X7 Receptor
98.91%
Gardenoside  
P2X3 Receptor
 
P2X7 Receptor
99.55%
NF279
p2x1 Receptor
    ≥98.0%
GW791343 dihydrochloride    
P2X7 Receptor, pIC50: 6.9-7.2
98.03%
HEI3090    
P2X7 Receptor
99.04%
EVT-401    
P2X7 Receptor
99.89%
RO-3 
P2X2 Receptor
P2X3 Receptor
  
Gefapixant citrate  
P2X3 Receptor
  99.23%
Blue FPG-A trisodium
p2x1 Receptor, IC50: 35.5 μM
    
P2X3 antagonist 38  
P2X3 Receptor, IC50: 0.132 μM
  
P2X4 antagonist-4   
P2X4 Receptor, IC50: 8 μM
 
Minodronic acid-d4 
P2X2 Receptor
P2X3 Receptor
  
(S)-JNJ-54166060    
P2X7 Receptor
P2X4 antagonist-2   
P2X4 Receptor, IC50: 24 nM
 
P2X4 antagonist-1   
P2X4 Receptor, IC50: 15 nM
 99.89%
P2X7 receptor antagonist-3    
hP2X7R, IC50: 4.2 nM
rP2X7R, IC50: 6.8 nM
Opiranserin  
P2X3 Receptor
  
PPADS
p2x1 Receptor, IC50: 68 nM
P2X2 Receptor, IC50: 214 nM
   
α,β-Methylene-ATP dilithium
p2x1 Receptor
 
P2X3 Receptor
 
P2X7 Receptor
GW791343 trihydrochloride    
P2X7 Receptor, pIC50: 6.9-7.2
NF449
p2x1 Receptor